drugset
drugset / Trial / NCT05851443

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443 ↗

Phase 2 Active not recruiting 247 enrolled Incyte Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Timeline

Start
2023-07-11
Primary completion
2026-11-20
Completion
2027-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Povorcitinib Small molecule — —

Indications

asthma